Dynamic Changes in Human Microbiome Predict the Risk of Adverse Outcomes in Patients With Acute Ischemic Stroke: a Multicenter Prospective Cohort Study
NCT ID: NCT06240468
Last Updated: 2024-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2022-02-10
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To explore the predictive value of human microbiome and its metabolome for adverse prognosis in patients with acute ischemic stroke (AIS).
(2) Secondary purposes
1. To explore the characteristics of cross-regional disturbance of human microbiome in stroke patients;
2. To investigate the characteristics and rules of bacterial flora changes before and after recurrent apoplexy;
3. Markers closely related to AIS prognosis and cognitive emotional complications were excavated by metagenomic, metabolic, peptide and imaging groups.
4. To explore the relationship between serum markers of ultra early stage and prognosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiomics Targeting Microbiome Associated Changes in Stroke Patients (StrokeMicroBiomics)
NCT04315922
Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Treatments to Improve Neurological Evolution and Functional Status of Stroke Patients.
NCT04795687
Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of Cerebral Hemorrhage
NCT05551923
The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
NCT07269288
Early Neurological Deterioration in Patients With Acute Ischemic Stroke
NCT03703986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Baseline data collection and discharge neurological function score were completed for the enrolled AIS patients before discharge, and the final diagnosis, stroke etiology classification, lifestyle survey (1 year ago), and relevant examination and treatment during hospitalization were recorded. Neurological function score, lifestyle survey, new cardiovascular and cerebrovascular events and biological specimen collection (blood, urine, feces, periodontal swab) were recorded during outpatient visits 3 months and 6 months after admission. Telephone follow-up was conducted 12 months after admission, mRS Score, ADL score and new cardiovascular and cerebrovascular events were recorded.
For the patients (750 cases) who met the criteria for inclusion in the cognitive emotion subcohort, outpatient emotional and cognitive psychological assessment was also required before discharge, 3 months and 6 months after admission on the basis of the AIS cohort.
For the subcohort with recurrence within 1 year, only data collection during hospitalization (baseline hospitalization data) and biological specimen collection during hospitalization (residual blood after the first laboratory examination was retained for patients in the very early stage, and blood, urine, feces, and periodontal swabs were collected the next day after admission and before discharge. As the time of fecal sample collection is difficult to control, it only needs to be 48 hours between hospitalization), and no follow-up will be conducted after discharge.
In addition, 500 patients without stroke were recruited as healthy control group according to the prescribed inclusion criteria.
No randomization or any study protocol-driven treatment will be administered or provided to the subject during the study. If clinically applicable, treatment decisions and treatment options are made at the discretion of the treating physician.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AIS patient
AIS inclusion criteria
(1) Inclusion criteria
1. Meet the diagnostic criteria for AIS or TIA;
2. Age 18-80 years old;
3. within 7 days of the onset of stroke;
4. Sign informed consent, provide relevant medical history and biological specimens;
5. Have lived in the local city for the last three years.
(2) Exclusion criteria
1. Patients with recurrent stroke within the past year when first enrolled;
2. mRS \> 2 points before stroke onset;
3. malignant tumor;
4. Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase \>2 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal);
5. History of drug abuse and chemical poisoning (e.g. pesticide poisoning);
6. In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected.
not have
not have
Cognitive/emotional subcohort
(I) Inclusion criteria:
1. It has been included in the AIS queue, meeting the inclusion criteria of the main AIS queue;
2. NIHSS≤15; (II) Exclusion criteria:
(1) Patients with aphasia and unable to cooperate in completing the cognitive/emotional assessment during the study; (2) previous severe mental disorder and dementia (AD8 scale score ≥2); (3) A history of severe anxiety and depression; (4) Previous history of seizures.
not have
not have
healthy person
health
not have
not have
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
not have
not have
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-80 years old
* Within 7 days of the onset of stroke
* Sign informed consent, provide relevant medical history and biological specimens
* Have lived in the local city for the last three years
Exclusion Criteria
* mRS \> 2 points before stroke onset
* malignant tumor
* Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase \>2 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal)
* History of drug abuse and chemical poisoning (e.g. pesticide poisoning)
* In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhujiang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CALM2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.